



DXS International plc

Investor Presentation

March 2021



BUSINESS OVERVIEW

- ▶ Provide **Clinical Decision Support** to **approximately 27% of GP practices** throughout the UK.
- ▶ Use our **proprietary technology** of software solutions deployed at clinical sites and interfaced with electronic health records.
- ▶ An **annual turnover** of £3,4 million.
- ▶ Have **invested over £4 million** into the development of new **Expert Clinical Decision Support solutions**.



CLINICAL DECISION SUPPORT SOLUTIONS (CDSS)



Clinicians: Provide treatment decisions in form of guidance, alerts and reminders in their workflow.



CLINICAL DECISION SUPPORT SOLUTIONS (CDSS)



Patients: Communicate with patients via SMS messaging or an app sending reminders & requests for measurements such as blood pressure & sending lifestyle advice.



BENEFITS OF CLINICAL DECISION SUPPORT

Gold standard treatment advice exists which, if implemented according to existing guidelines, will result in the best possible outcomes for patients, clinicians and healthcare payers.



THE CLINICAL DECISION SUPPORT CHALLENGE

Difficult for busy clinicians to implement complex treatment guidance



Guidelines for LTC are
long & complex

Hypertension Guideline:
300 pages

Diabetes Guideline:
278 pages

The challenge is to provide
summarised advice in the workflow



THE CLINICAL DECISION SUPPORT CHALLENGE

Exacerbated by shortage of GPs



GPs


150 million consultations (50%) for people with LTC

Time per consultation in the UK is 10 minutes

Shortage of 6,000 GPs in the UK


49% of GPs plan to reduce hours, 11% plan to retire in 3 years, & 15% plan career change.

SOLVING THE PROBLEM



EVOLUTION OF OUR CLINICAL DECISION SUPPORT

IN PURSUIT OF EXCELLENCE



OUR SOLUTION SUITE – MODULAR APPROACH



Point-of-Care – DXS’s live solution & revenue earner.


CompleteCare - Clinical Tools & Template solution to navigate complex consultations. Marketing & sales in progress.

ExpertCare – New Expert Hypertension clinician prescribing solution – Pilot Phase in progress.

MyVitalCare – New Expert patient facing mobile Hypertension solution – Pilot in May 2021.



OUR EVOLUTION – EXPERT RULES BASED ALGORITHMS FOCUSING ON LONG TERM CONDITIONS



THE RISING THREAT OF LONG TERM CONDITIONS

30%

of global population have LTCs.

70%

of global healthcare spend by LTC patients.

20%

of UK population will be over 65 by 2030.

£££

LTC's are biggest financial challenge for healthcare funders.

60%

of LTC patients have more than one LTC.


10m

Projected global shortage of doctors & nurses by 2030 – 6,000 GPs in UK.



OUR EXPERT CDSS SOLUTION – STEP ONE

HYPERTENSION



THE UK HYPERTENSION OPPORTUNITY

A 30% market penetration of our ExpertCare solution in the UK could



Avert **5,000 strokes & 3,000 heart attacks p.a.**



Save over **one million** GP hours pa.



Significantly improve a **Practice's profitability.**



Save the NHS £30 million p.a.



OUR UK HYPERTENSION PILOTS

TICKING THE BOXES

**From
50%**

Only 50% of hypertensive patients are compliant with current treatment guidelines.

**To
74%**

48% improvement in compliance to 74% after using ExpertCare.

**Save GP
Time**

By enabling Nurses & Pharmacists to conduct hypertension reviews with minimal GP input.

90%

90% of clinicians are enthusiastic about the ExpertCare solution.



EXPERTCARE HYPERTENSION

CLEAR BENEFITS

328

Estimated GP hours saved
per practice p.a.

£25k

Amount saved on GP
time per practice.

£14k


Potential saving to NHS
p.a. per practice by
reducing heart attacks &
strokes.



Healthier, happier
Patients.



GROWING OUR UK BUSINESS



- ▶ Continue selling our DXS Point of Care & CompleteCare solutions.
- ▶ Following successful pilots, launch new Clinician and Patient facing Hypertension Expert Solution.
- ▶ Add new LTC diseases, such as diabetes, to our ExpertCare solution



INTERNATIONAL MARKET

Hypertension Tender Award – Turkey, Croatia, Italy, Sweden

Phase I Award

Effective March – May 2021
Phase I Grant awarded

Phases 2 & 3

Phases 2 & 3 over 20 months if we succeed with Phase I

90m

Number of Hypertensives in EU

Solutions

ExpertCare Hypertension solution

(www.hsmonitor-pcp.eu)



INTERNATIONAL MARKET USA

Clear US need
for
hypertension
solution

US Cardiologist & Family
Physicians endorse need
for ExpertCare solution.

Planned Pilot
Nov 2021

At select US sites

Secure
VARs

Appoint US Value Added
Resellers April 2022.

US
Potential

Target 10% of 108 million
hypertensives.



OUR ENDORSEMENTS

NHS
Accredited

DXS Point of Care
Centrally funded by NHS.

CE
Accredited

ExpertCare
Hypertension CE
accredited.

ISO
Accredited

Company ISO 27001
accredited.

NHS London
Procurement
Partnership

30 members consisting of
NHS Trusts, Hospital Trusts
and CCGs.

*Partnerships with EMIS, SystmOne and Vision giving secure access to
95% of UK patient records*



SUPPORTED BY OUR CUSTOMERS

“Meeting referral needs”

“Real time-saver”

“Keep up the good work!”

“Changed my decision”

“Intuitive, easy to use”

“Empower Nurses / Pharmacists”



Financial Summary

DXS INTERNATIONAL PLC.

Income Statement

Six months ended 31 October 2020

	Unaudited Group Six months ended 31 Oct 2020 Continuing Operations £	Audited Group Year ended 30 April 2020 Continuing Operations £
Turnover	1,716,424	3,279,787
Gross Profit	1,539,057	2,961,363
Profit for the period	224,825	428,502

Financial Summary

DXS INTERNATIONAL PLC.

Salient Features extracted from the Statement of Financial Position

As at 31 October 2020

	Unaudited Group at 31 Oct 2020 £	Audited Group at 30 April 2020 £
Development expenditure	4,095,805 -----	3,799,540 -----
Cash at bank and in hand	1,207,305 -----	1,010,645 -----
Revenue in advance	(482,358) -----	(571,094) -----
Shareholders' funds	3,875,304 =====	3,650,479 =====

SUMMARY OF OPPORTUNITIES

- **Grow UK market.**
- **Win Phases 2 & 3 of EU Tender.**
- **Establish successful US pilot.**
- **Add new Long Term Conditions to Expert Engine.**
- **Continue innovating AI and DNA and Personalised Health.**



DXS International plc

THANK YOU

